The Effect of Short Term Finasteride Therapy on Blood Loss with Transure- thral Resection of the Prostate (TURP)
Keywords:
finasteride, blood loss, TURPAbstract
Objectives: To study effect of short-term preoperative treatment with finasteride, compared with non finasteride treatment, may reduce the blood loss on the patients with transurethral resection of the prostate (TURP).
Methods: This two group comparative randomized control trial, single -center, 6-month pilot study was designed to study the effect of at least 1 month preoperative treatment with finasteride (5 mg daily) on blood loss during surgery in 36 men who required TURP. The surgical blood loss was measured by preoperative and postoperative CBC and irrigating fluid for hemoglobin detection.
Results: Finasteride could not reduce blood loss in small prostate gland (resection weight <20 g) but in the large prostate gland (resection weights greater than 20 g) finasteride could reduce blood loss on patients with transurethral resection of the prostate. (mean 324 and 547 ml for finasteride short-term treatment versus control group).
Conclusions: Preoperative treatment with finasteride could not reduce blood loss in TURP, but in the large prostate gland could reduce blood loss.
References
Uchida T, Ohori M, Soh S, et al. Factors influencing morbidity in patients undergoing transurethral resection of the prostate. Urology 1999; 53: 98-105.
Madersbacher S, Maberger M. Is transurethral resection of the prostate still justified? BJU Int 1999; 83: 227-7.
Olsson J, Nilsson A, Hahn RG. Symptoms of the transurethral resection syndrome using glycine the irrigant. J Urol 1995; 154: 123-8.
Hahn RG, Sandfeldt L, Nyman CR. Double-blind randomized study of symptoms associated with absorption of glycine 1.5% or mannitol3% during transurethral resection of the prostate. J Urol 1998; 160: 397-401.
Oesterling JE. Endocrine therapies for symptomatic benign prostatic hyperplasia. Urology 1994; 43: 7-16.
Lepor H, Williford WO, BarryMJ, et al. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. N Engl J Med 1996; 335: 533-9.
McConnell JD, Bruskewitz R, Walsh P, et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N Engl J Med 1998; 338: 557-63.
Puchner PJ, Miller Ml. The effects of finasteride on hematuria associated with benign prostatic hyperplasia: preliminary report. J Urol 1995; 154:1779-82
Puchner PJ, Miller Ml. The effects of finasteride on hematuria associated with benign prostatic hyperplasia: long term follow-up. Urology 1998; 51: 237-240.
Sieber PR, Rommel FM, Huffnagle HW, Breslin JA, Agusta VE, Harpster LE. The treatment of gross hematuria secondary to prostatic bleeding with finasteride. J Urol 1998; 159: 1232-3.
Marshall S, Narayan P. Treatment of prostatic bleeding; suppression of angiogenesis by androgen deprivation. J Urol 1993; 149: 1553-4.
Foley SJ, Bailey DM. Microvessel density in prostatic hyperplasia. BJU Int 2000; 85: 70-3.
Lekas E, Bergh A, Damber JE. Effects of finasteride and bicalutamide on prostatic blood flow in the rat. BJU Int. 2000; 85: 962-5.
Chakrabarti P, Salas N, Herbert FB, et al Reduction of prostatic blood flow by finasteride. J Urol 1997; 157: 190.
Bailey DM, Forley SJ, Wedderburn A. Effect of finasteride on microvessel density (MVD) in patients with recurrent hematuria related to prostatic hypertrophy(BPH)(abtract). J Urol 1999; 161: 363.
John F, Donohue, Dickon Hayne, et al. Randomized, placebo-controlled trial showing that finasteride reduces prostatic vascularity rapidly within 2weeks. BJU 2005; 96:1319-22.
Joseph IB, Nelson JB, Denmeade SR, Isaacs JT. Androgens regulate vascular endothelial growth factor content in normal and malignant prostatic tissue. Clin Cancer Res 1997; 3: 2507-11.
Haggstrom S, Lissbrant IF, Bergh A, Damber JE. Testosterone induces vascular endothelial growth factor synthesis in the ventral prostate in castrated rats. J Urol 1999; 161: 1620-5.
Pareek G, Shevchuk M, Armenakas NA, et al. The effect of finasteride on the expression of vascular endothelial growth factor and micro-vessel density; a possible mechanism for decreased prostatic bleeding in treated patients. J Urol 2003; 169: 20-3.
